Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851227 · ClinicalTrials.gov registry record · Phase 1
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
A Phase 1 study of Liver Disease and Hyponatremia, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00851227: Completed Phase 1 study of Liver Disease and Hyponatremia, sponsored by Cumberland Pharmaceuticals.
NCT00851227 is a Phase 1 study of Liver Disease and Hyponatremia that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 26 participants, below the 794-participant average among 14 other Liver Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00851227, a Phase 1 study of Liver Disease and Hyponatremia, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function
Conditions Studied
Interventions
- DRUG conivaptan hydrochloride
Study Locations (1)
Florida
- - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00851227 record still lists
NCT00851227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 794-participant average among 14 other Liver Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which conivaptan hydrochloride is the first listed.
NCT00851227 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00851227 about?
NCT00851227 is a clinical study titled "Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function". A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function
What is the current status of trial NCT00851227?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2009-02. Estimated completion is 2010-01.
What conditions does trial NCT00851227 study?
This clinical trial studies the following conditions: Liver Disease, Hyponatremia.
What interventions are being tested in trial NCT00851227?
The interventions under investigation include: conivaptan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00851227?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00851227 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00851227's enrollment target sits among peer trials
26 12th of 14 higher than 3 of 14 other Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hepatic Impairment Study
COMPLETED · Phase 1
-
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
COMPLETED · Phase 1
-
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
COMPLETED · Phase 1
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
ACTIVE NOT RECRUITING
-
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia